Table 3 Simulated treatment sequences, duration of treatments per patient, and survival in mCRPC

% of patients receiving each line of treatment

100%

88.1%

72.7%

54.2%

29.4%

  Mean duration per patient (95%CI)^*

8.5 (8.4-8.6)

4.3 (4.3-4.4)

7.1 (7.0-7.1)

10 (9.9-10.2)

14.6 (14.3-14.9)

  Median duration per patient (IQR)^*

8 (5–12)

4 (3–6)

7 (7–8)

9 (4–17)

15 (6–24)

  Mean Survival (95%CI)^**

28.1 (27.7-28.4)

22.1 (21.7-22.4)

21.3 (20.9-21.6)

18.8 (18.4-19.1)

15.2 (14.9-15.5)

  Median Survival (IQR)^**

25 (14–40)

19 (7–24)

18 (9–32)

16 (8–28)

16 (7–24)

Alternate model

Treatment sequence

AA

AAwd

Abiraterone

Docetaxel

Cabazitaxel

OtherTx

% of patients receiving each line of treatment

100%

88.0%

72.6%

47.4%

35.4%

26.9%

  Mean duration per patient (95%CI)^*

8.6 (8.5-8.7)

4.4 (4.3-4.4)

20.2 (19.9- 20.4)

7.0 (7.0-7.1)

5.7 (5.6-5.8)

15.0 (14.7-15.4)

  Median duration per patient (IQR)^*

8 (5–12)

4 (3–6)

19 (9–35)

7 (7–8)

5 (4–7)

16 (7–24)

  Mean Survival (95%CI)^**

37.3 (36.8-37.8)

32.5 (32.0-32.9)

33.8 (33.4.0-34.3)

20.4 (20.1-20.8)

17.6 (17.3-17.9)

15.7 (15.4-16.0)

  Median Survival (IQR)^**

34 (15–56)

30.0 (12–50)

32 (17–48)

18 (9–34)

17 (8–28)

17 (8–24)